Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of LBL-024 combination therapy in advanced solid tumors
CTR20250158Phase 2Active
- Sponsor
- Leads Biolabs
- Start
- Jul 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of opamtistomig in Nonhematologic neoplasms (3 arms), sponsored by Leads Biolabs. Primary endpoint: Objective response rate. Started Jul 2025; status: active.
02
Drugs
opamtistomig
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20250158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250158.